RemeGen Co (SHSE:688331) Beginning Cash Position: ¥1,178 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688331 RemeGen Co Ltd SHSE:688331
47 GF Score
Price ¥114.84
GF Value ¥244.53
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is RemeGen Co Beginning Cash Position?

RemeGen Co SHSE:688331 +0.62% 47 Beginning Cash Position is ¥1,178 Mil as of Jun. 2026. GuruFocus rates SHSE:688331 with a GF Score™ of 47/100 and a GF Value™ of ¥244.53 (Possible Value Trap). The stock has 5 warning signs investors should review.

RemeGen Co's Beginning Cash Position for the quarter that ended in Jun. 2026 was ¥1,178 Mil.

RemeGen Co's quarterly Beginning Cash Position increased from Jun. 2025 (¥762 Mil) to Dec. 2025 (¥1,314 Mil) but then declined from Dec. 2025 (¥1,314 Mil) to Jun. 2026 (¥1,178 Mil).

RemeGen Co's annual Beginning Cash Position declined from Dec. 2023 (¥2,086 Mil) to Dec. 2024 (¥729 Mil) but then increased from Dec. 2024 (¥729 Mil) to Dec. 2025 (¥802 Mil).

RemeGen Co Beginning Cash Position Related Terms

RemeGen Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Beginning Cash Position Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial - 1,873.05 2,086.02 729.36 802.48

RemeGen Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 729.53 762.34 762.44 1,313.95 1,177.98
SHSE:688331
47GF Score
RemeGen Co Ltd SHSE:688331
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of ¥1,178 Mil mean?
RemeGen Co (SHSE:688331) has a Beginning Cash Position of ¥1,178 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on RemeGen Co and its competitors.
Is RemeGen Co's Beginning Cash Position too high?
RemeGen Co's current Beginning Cash Position is ¥1,178 Mil. Overall, RemeGen Co has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Beginning Cash Position compare to VRTX and REGN?
RemeGen Co's Beginning Cash Position of ¥1,178 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on RemeGen Co and its competitors. RemeGen Co's current Beginning Cash Position is ¥1,178 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (SHSE:688331) is currently considered Possible Value Trap. The stock's GF Value™ is ¥244.53, compared to a current price of ¥114.84 — trading 53% below its estimated fair value. The current Beginning Cash Position is ¥1,178 Mil. RemeGen Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For RemeGen Co (SHSE:688331), the current Beginning Cash Position is ¥1,178 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (SHSE:688331) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of ¥114.84 is trading 53% below its estimated GF Value™ of ¥244.53. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for SHSE:688331:

  • Beginning Cash Position: ¥1,178 Mil
  • GF Value™: ¥244.53 vs. price of ¥114.84 (53% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
47GF Score

Get the complete analysis for SHSE:688331

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥114.84
Price
¥244.53
GF Value